Triple-negative breast cancer (TNBC), characterized by an absence of estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER2) [3], displays the poorest clinical outcomes, owing to early recurrence and a propensity for distant visceral metastases [4]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.